Poster Topical Area: Obesity

Location: Hall D

Poster Board Number: 677

P23-050 - A multi-center, randomized, double-blind, placebo controlled study of the dietary supplements (Slim and Triplex) for weight management in subjects with a BMI ≥27

Sunday, Jun 10
8:00 AM – 6:00 PM

Objectives:

The present study investigated the safety and efficacy of dietary supplement regimens on weight loss in overweight and obese men and women with a BMI ≥27 kg/m2 over 8 weeks.




Methods:


In a multi-center, double-blind, placebo-controlled, randomized trial, 196 subjects were randomly assigned to either Plexus Slim (containing chromium, green coffee bean extract and polydextrose, etc.) or Plexus Triplex supplements, including Slim, Bio Cleanse (containing magnesium and bioflavonoid, etc.), and ProBio5 (containing probiotics and digestive enzymes), or the corresponding placebo controls. During the study, subjects were guided to adhere to a Mediterranean Diet.




Results:


Of the 175 subjects who completed the study, in the Slim treatment group had lost a mean of -4.46lb (SD = 6.97) body weight, while the Slim placebo group had a mean -2.12lb (SD=4.31) weight loss. There was a substantial mean decrease in body weight (-6.11 lb, SD = 5.97) in the Triplex group, where as a small increase in weight (1.37± 3.86) over time in the placebo group group (p<0.01). The Triplex group had a much greater weight loss than Slim group (p<0.001), suggesting a substantially greater effect for Triplex. When using a body-mass index (BMI) cutoff of >35, significantly greater reductions in both weight (-6.59 vs. -2.67 lb, p = .025) and BMI (-1.25 vs. -0.52, p = .033) were found in the Slim group, compared with its corresponding placebo group. Significantly greater reductions in both weight (-8.84 vs. -0.42 lb, (p < .001) and BMI (-2.32 vs. 1.13, p = .002) were also found in the Triplex treatment group, compared with the placebo group. There was a significant difference in the proportion of subjects achieving at least 5% of weight loss between the treatment and placebo groups (p = 0.01). There were 11.1% and 25.6% of individuals in Slim and Triplex groups, respectively, who lost at least 5% of their initial body weight, while no individuals were found to have lost this much weight in the both placebo groups. No clinically significant adverse effects were observed.




Conclusions:


Both Plexus Slim and Triplex administrations are safe and effective adjunct to an eight-week diet weight loss program by inducing weight loss. In particular, both Slim and Triplex demonstrated significantly greater reductions in body weight and body fat in subjects who have heavier initial body weight (BMI>35).




Funding Source: This study was funded by Plexus Worldwide.

CoAuthors: Marek Piatek, MD – Aspire Clinical Studies; Debbie Gonzales – Aspire Clinical Studies

T. Alan Jiang

VP, Research and Development
Plexus Worldwide
Scottsdale, Arizona